Compare Stocks: SRPT, CTMX, EDIT, and ALKS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$45.34 -0.1%	$44.06	$27.00 ▼ $55.67	$7.61B	0.32	1.95 million shs	1.11 million shs
CTMX CytomX Therapeutics	$2.34 +2.2%	$2.83	$2.16 ▼ $8.21	$509.88M	2.21	3.44 million shs	4.94 million shs
EDIT Editas Medicine	$2.67 -8.9%	$2.76	$1.66 ▼ $3.94	$410.06M	2	2.47 million shs	2.91 million shs
SRPT Sarepta Therapeutics	$18.62 -3.2%	$19.24	$14.68 ▼ $24.68	$1.97B	0.38	2.84 million shs	1.32 million shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+3.92%	+11.84%	-7.45%	+44.17%
CTMX CytomX Therapeutics	0.00%	+0.86%	-11.03%	-24.52%	-28.22%
EDIT Editas Medicine	0.00%	+11.25%	+5.95%	+3.49%	-12.17%
SRPT Sarepta Therapeutics	0.00%	+5.02%	+5.98%	+25.30%	-20.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$45.34 -0.1%	$44.06	$27.00 ▼ $55.67	$7.61B	0.32	1.95 million shs	1.11 million shs
CTMX CytomX Therapeutics	$2.34 +2.2%	$2.83	$2.16 ▼ $8.21	$509.88M	2.21	3.44 million shs	4.94 million shs
EDIT Editas Medicine	$2.67 -8.9%	$2.76	$1.66 ▼ $3.94	$410.06M	2	2.47 million shs	2.91 million shs
SRPT Sarepta Therapeutics	$18.62 -3.2%	$19.24	$14.68 ▼ $24.68	$1.97B	0.38	2.84 million shs	1.32 million shs

7 Energy Stocks to Buy and Hold Forever

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	+3.92%	+11.84%	-7.45%	+44.17%
CTMX CytomX Therapeutics	0.00%	+0.86%	-11.03%	-24.52%	-28.22%
EDIT Editas Medicine	0.00%	+11.25%	+5.95%	+3.49%	-12.17%
SRPT Sarepta Therapeutics	0.00%	+5.02%	+5.98%	+25.30%	-20.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.67	Moderate Buy	$54.38	19.93% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	408.55% Upside
EDIT Editas Medicine	2.71	Moderate Buy	$5.83	118.48% Upside
SRPT Sarepta Therapeutics	2.00	Hold	$22.88	22.85% Upside

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/16/2026	ALKS Alkermes	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$55.00
10/13/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/13/2026	CTMX CytomX Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/8/2026	EDIT Editas Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Equal Weight ➝ Overweight	$4.00 ➝ $6.00
10/8/2026	SRPT Sarepta Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Perform	$19.00 ➝ $17.00
10/5/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/5/2026	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell	$5.00
9/30/2026	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$23.00 ➝ $20.00
9/28/2026	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Underperform
9/24/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	5.15	$1.67 per share	27.08	$11.02 per share	4.11
CTMX CytomX Therapeutics	$76.20M	6.69	N/A	N/A	$0.58 per share	4.03
EDIT Editas Medicine	$40.52M	10.12	N/A	N/A	$0.28 per share	9.54
SRPT Sarepta Therapeutics	$2.20B	0.89	N/A	N/A	$10.89 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	119.32	146.26	N/A	3.96%	4.15%	2.19%	11/3/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	13.90	0.34	-13.48%	-1.60%	-0.66%	11/5/2026 (Confirmed)

Latest SRPT, CTMX, EDIT, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	EDIT Editas Medicine	-$0.21	N/A	N/A	N/A	$4.54 million	N/A
11/5/2026	Q3 2026	CTMX CytomX Therapeutics	-$0.09	N/A	N/A	N/A	$10.38 million	N/A
11/5/2026	Q3 2026	SRPT Sarepta Therapeutics	$0.0740	N/A	N/A	N/A	$352.20 million	N/A
11/3/2026	Q3 2026	ALKS Alkermes	-$0.0816	N/A	N/A	N/A	$463.48 million	N/A
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
CTMX CytomX Therapeutics	N/A	9.36	9.36
EDIT Editas Medicine	N/A	3.19	3.19
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
CTMX CytomX Therapeutics	67.77%
EDIT Editas Medicine	71.90%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
CTMX CytomX Therapeutics	3.80%
EDIT Editas Medicine	3.10%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
SRPT Sarepta Therapeutics	835	105.63 million	98.34 million	Optionable

SRPT, CTMX, EDIT, and ALKS Headlines

Recent News About These Companies

RBC Capital Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

October 31 at 12:01 PM | theglobeandmail.com

Sarepta Therapeutics (SRPT) Earnings Preview Puts Its Fair Value Back In Focus

October 30 at 8:58 PM | finance.yahoo.com

Leerink keeps USD 20.00 target for Sarepta Therapeutics stock

October 29 at 2:50 PM | ad-hoc-news.deA

Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?

October 29 at 11:02 AM | zacks.com

Sarepta Therapeutics (SRPT) Set to Announce Quarterly Earnings on Thursday

October 29 at 3:10 AM | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

October 28, 2026 | americanbankingnews.com

Sarepta Therapeutics to Present at Upcoming Investor Conferences - October 26, 2026

October 26, 2026 | biospace.comB

Sarepta Therapeutics' PD Biomarker Data From FSHD, DM1 Studies Will Be in Focus, Wedbush Says

October 26, 2026 | finance.yahoo.com

Sarepta Therapeutics to Present at Upcoming Investor Conferences

October 26, 2026 | businesswire.com

Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst

October 22, 2026 | theglobeandmail.com

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

October 22, 2026 | businesswire.com

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Sarepta Therapeutics (SRPT) and BioNTech SE (BNTX)

October 20, 2026 | theglobeandmail.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8.2% - Time to Buy?

October 20, 2026 | marketbeat.com

H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock

October 20, 2026 | ad-hoc-news.deA

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating a 26.53% Potential Upside Amidst Biotechnology Challenges

October 19, 2026 | directorstalkinterviews.com

Sarepta presents 80 percent DM1 data for Sarepta Therapeutics stock

October 18, 2026 | ad-hoc-news.deA

What Is The Case For Waiting On Moderna Stock?

October 17, 2026 | trefis.comT

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

October 16, 2026 | theglobeandmail.com

Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says

October 16, 2026 | finance.yahoo.com

Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35

October 16, 2026 | tipranks.com

Sarepta Therapeutics, Inc. Presents New Preclinical Data Demonstrating Robust Knockdown Of Pathogenic DMPK RNA In The Nucleus With SRP-1003 In DM1 At 2026 Oligonucleotide ...

October 15, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SRPT, CTMX, EDIT, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

$45.34 -0.03 (-0.07%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$45.32 -0.02 (-0.03%)

As of 10/30/2026 07:39 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

CytomX Therapeutics NASDAQ:CTMX

$2.34 +0.05 (+2.18%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$2.37 +0.03 (+1.07%)

As of 10/30/2026 07:30 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.67 -0.26 (-8.87%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$2.67 0.00 (-0.07%)

As of 10/30/2026 07:55 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sarepta Therapeutics NASDAQ:SRPT

$18.62 -0.61 (-3.17%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$18.77 +0.15 (+0.83%)

As of 10/30/2026 07:52 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, CTMX, EDIT, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, CTMX, EDIT, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, CTMX, EDIT, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, CTMX, EDIT, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

CytomX Therapeutics NASDAQ:CTMX

Editas Medicine NASDAQ:EDIT

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools